trelstar has been researched along with Metrorrhagia* in 3 studies
3 other study(ies) available for trelstar and Metrorrhagia
Article | Year |
---|---|
Uterine adenocarcinoma after GnRH agonist treatment.
We report endometrial adenocarcinoma in two patients shortly after suspending GnRH-agonist treatment for menometrorrhagia and uterine fibromata. Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Female; Humans; Injections, Intramuscular; Leiomyoma; Leuprolide; Metrorrhagia; Middle Aged; Myometrium; Neoplasms, Second Primary; Triptorelin Pamoate; Uterine Neoplasms | 2000 |
[Use of a GnRH analogue in the treatment of certain forms of endometrial hyperplasia associated with menometrorrhagia].
Hyperestrogenism is a powerful factor inducing the development of endometrial hyperplasia that in its turn may represent the first step in the natural history of endometrial carcinoma. During menopause it is possible to have a condition to relative hyperestrogenism induced by a residual hormonal activity and by aromatisation of androgens in the adipose tissue. Therapeutical approach in this pathology aims to control hyperplastic development of the endometrial mucosa and to exclude menometrorrhagia. This study has been performed according to an open uncontrolled design in 14 women (4 menopausal women) with abnormal uterine bleeding and hysteroscopic endometrial cystic or adenomatous hyperplasia. At the beginning and at the end of treatment all patients underwent routine biohumoral blood-tests, hysteroscopy and diagnostic curretage. The GnRH analogue (tryptorelin) 3.75 mg 1 ampoule i.m. every 28 days was administered during a 6-month treatment cycle. At the end of therapy bleeding had disappeared in all menopausal women; in the premenopausal group 8 patients have shown a normal menstrual cycle while 2 are still amenorrhoic. The final hysteroscopic evaluation displayed atrophic endometrium in 9 patients and simple proliferative endometrium in 5 cases. Safety was excellent: 3 cases of slight increase of systolic blood pressure and 1 case of slight increase of weight took place. Our results demonstrate therapeutic efficacy of GnRH analogues in the treatment of endometrial hyperplasia with menometrorrhagia either in premenopausal or menopausal women. Topics: Aged; Dose-Response Relationship, Drug; Endometrial Hyperplasia; Female; Gonadotropin-Releasing Hormone; Humans; Menopause; Menorrhagia; Metrorrhagia; Middle Aged; Premenopause; Triptorelin Pamoate | 1995 |
[Isolated metrorrhagia in a prepubertal child caused by functional ovarian cyst].
The authors report the case of a 10-year-old girl, without any sign of pubertal development, who showed repeated metrorrhagia, related to a functional ovarian cyst. Cyproterone acetate therapy gave only a transient remission of the metrorrhagia. A complete remission was obtained with a 6 months treatment with an LHRH analog. Topics: Child; Female; Gonadotropin-Releasing Hormone; Humans; Luteolytic Agents; Metrorrhagia; Ovarian Cysts; Triptorelin Pamoate | 1988 |